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Krabbe disease is a devastating neurodegenerative disorder caused by defects in the 
lysosomal hydrolase galactocerebrosidase (GALC). Over 100 different mutations have been 
identified in the GALC gene and are located throughout the protein. Here, we identify a 
number of distinct molecular mechanisms underlying the disease pathogenesis, including 
misfolding and incorrect post-translational modification resulting in the lack of delivery of 
GALC (green) to lysosomal compartments (red, cathepsin D). Understanding these 









Krabbe disease is a severe, fatal 
neurodegenerative disorder caused by defects in 
the lysosomal enzyme galactocerebrosidase 
(GALC). The correct targeting of GALC to the 
lysosome is essential for the degradation of 
glycosphingolipids including the primary lipid 
component of myelin. Over 100 different mutations 
have been identified in GALC that cause Krabbe 
disease but the mechanisms by which they cause 
disease remain unclear. We have generated 
monoclonal antibodies against full-length human 
GALC and used these to monitor the trafficking and 
processing of GALC variants in cell-based assays 
and by immunofluorescence microscopy. Striking 
differences in the secretion, processing and 
endosomal targeting of GALC variants allows the 
classification of these into distinct categories. A 
subset of GALC variants are not secreted by cells, 
not proteolytically processed, and remain trapped in 
the ER; these are likely to cause disease due to 
protein misfolding and should be targeted for 
pharmacological chaperone therapies. Other GALC 
variants can be correctly secreted by cells and 
cause disease due to catalytic defects in the 
enzyme active site, inappropriate post-translational 
modification or a potential inability to bind essential 
co-factors. The classification of disease 
pathogenesis presented here provides a molecular 
framework for appropriate targeting of future Krabbe 
disease therapies.  
 
Introduction 
Krabbe disease, also known as globoid cell 
leukodystrophy, is a rare, autosomal recessive 
disorder in which extensive demyelination is 
accompanied by rapid, fatal neurodegeneration. 
Krabbe disease is caused by defects in the 
lysosomal enzyme galactocerebrosidase (GALC) 
that is essential for the catabolism of 
galactosphingolipids, including the primary lipid 
component of myelin, galactocerebroside. The 
molecular understanding of Krabbe disease has 
been aided by the sequence characterization of the 
human gene, structure determination of the GALC 
protein and via the study of various animal models 
of the disease (1-5). The GALC protein is produced 
and glycosylated in the endoplasmic reticulum (ER) 
and trans-Golgi network (TGN) where it is post-
translationally modified by N-linked glycosylation at 
four sites (3). GALC then becomes cargo for the 
cation-independent mannose-6-phosphate receptor 
(M6PR) which targets it to lysosomes either directly 
from the trans-Golgi network (TGN) or indirectly via 
secretion and re-uptake (6). It is in the 
endolysosome/lysosome that GALC processes lipid 
substrates. Sphingolipid degradation by lysosomal 
hydrolases also requires non-enzymatic 
sphingolipid activator proteins known as saposins. 
In rare cases, Krabbe disease can be caused by 
lack of functional saposin A (7). 
Despite these molecular insights into GALC function 
the cellular events that result in apoptosis of myelin-
forming oligodendrocytes and Schwann cells of the 
central and peripheral nervous systems remains 
poorly understood. Krabbe disease severity and 
progression are highly variable and the age of 
clinical onset can vary from the first few weeks of 
life (early infantile) through late-infantile and juvenile 
into adult presentations (late-onset). To date, 147 
different mutations in the GALC gene have been 
catalogued for the Online Metabolism and 
Molecular Bases of Inherited Disease (OMMBID) 
(8). 
Currently, the only available treatment for Krabbe 
disease is haematopoietic stem cell transplantation 
but as this cannot repair damage that has already 
occurred it must be initiated before the onset of 
symptoms. For this reason early diagnosis is crucial 
and has led to the establishment of several 
newborn screening programmes (9). For mutations 
of known severity these screening programmes aid 
the rapid implementation of treatment. However, for 
newly identified mutations the clinical severity 
remains uncertain.  
Understanding the pathogenesis of specific 
mutations in GALC is not only important for 
predicting the severity of newly identified mutations 
but is also important for determining which patients 
will be appropriate candidates for new treatments 
and combination therapies currently being 
developed (10-13). One such therapy being 
pursued for Krabbe disease and a number of 
related lysosomal storage diseases is 
pharmacological chaperone therapy (14-18). The 
goal of this approach is to treat patients with small 
molecules that can bind and stabilize partially 
misfolded enzyme that would otherwise remain 
trapped in the ER and be degraded by cellular 
quality-control pathways. This approach will not be 
appropriate for patients with large deletions in the 
GALC gene or for variants that are catalytically 
defective but must instead be targeted towards 
missense mutations that cause protein misfolding. 
For these reasons, it is important that we 
understand the molecular defects caused by 
specific mutations in GALC. Here we present the 
characterization of a series of Krabbe disease 
variants and highlight different molecular 




Missense mutations alter GALC secretion and 
processing 
In order to understand the different effects of 
missense mutations on GALC processing and 
trafficking a series of clinically-relevant variants 
were selected and expressed in HEK293T cells. 
Two numbering schemes are commonly used for 
GALC based on either the first or second 
methionine in the ER signal sequence. Here we are 
using the numbering based on the second 
methionine as this is consistent with the majority of 
the literature and the available structural data. For 




clarity we have included a table showing the 
equivalent numbering for the alternative start site 
(Table S1). FLAG-tagged GALC variants were 
detected in cell lysates and conditioned media by 
Western blot. Use of the anti-FLAG antibody in this 
case ensures that all GALC variants are detected 
using an identical epitope reducing any differences 
in binding of the antibody due specifically to the 
encoded mutation. All GALC variants are equally 
expressed in cells and individual bands are 
detected in cell lysates representing the addition of 
four N-linked glycans as GALC is produced and 
glycosylated in the ER and TGN (Fig. 1A and Fig. 
5B). However, only a subset of these variants is 
secreted and detected in the conditioned media 
suggesting a defect in trafficking beyond the ER-
TGN (Fig. 1A). For those variants that are secreted, 
only one band is detectable in the conditioned 
media identifying that these proteins possess 
uniform glycosylation and are therefore likely to 
have undergone correct processing before being 
secreted from cells. To confirm this, the sensitivity 
of GALC glycans to PNGaseF and EndoH was 
tested (Fig. 1B). The partially p ocessed protein in 
the cell lysates was susceptible to both treatments 
as expected, while the protein secreted into the 
media was primarily EndoH resistant confirming that 
the glycans had been correctly modified during their 
trafficking through the ER-TGN. 
The secretion profile illustrated here for a range of 
missense mutations provides an initial classification 
of GALC variants into those that are correctly 
processed and secreted and those that may cause 
disease due to misfolded protein being trapped in 
the ER. To confirm the delivery, or lack thereof, to 
the lysosomal compartment there is an additional 
post-translational processing step that occurs in the 
lysosome. Upon delivery to the lysosome, a loop on 
the surface of GALC is cleaved by a lysosomal 
protease. This event does not affect activity and is 
not likely to have any effect on the structure but can 
be detected by SDS-PAGE as 50- and 30-kDa 
bands (6, 19, 20). In the previous assays (Fig. 1A 
and B) there was no detectable band for the lower 
molecular weight cleavage product expected upon 
delivery of GALC to the lysosome. However, as 
detection of GALC involved using an antibody 
against the epitope tag it was possible that in the 
proteolytic environment of the endolysosomal 
system this tag is cleaved from the GALC protein 
restricting detection of the processed form. To 
overcome this, we generated a new panel of 
monoclonal antibodies raised against the full-length 
human GALC protein. We carried out an 
immunoprecipitation (IP) of GALC from cell lysates 
using either the FLAG antibody or two different 
mouse monoclonal antibodies (mAb1, mAb2). 
Following IP, bands were detected by Western blot 
using a rabbit polyclonal antibody raised against a 
peptide within the smaller C-terminal 30-kDa 
fragment (Fig. 2A).  For all samples the full-length 
uncleaved GALC is detectable at approx. 80 kDa. In 
both the IPs carried out with monoclonal antibodies 
an additional band is present at 30-kDa consistent 
with the fragment size following cleavage upon 
delivery to the lysosome. This band is not 
detectable in the IP using the anti-FLAG antibody 
highlighting the critical importance of appropriate 
antibodies for assay development. To confirm that 
the cleavage event occurs post-Golgi and thus is a 
measure of successful trafficking to lysosomes we 
carried out an uptake assay whereby conditioned 
media containing full-length uncleaved GALC was 
applied to untransfected HEK293T cells (Fig. 2B). 
The appearance of the 30-kDa fragment in 
untransfected cells treated with full-length GALC 
identifies that the detection of cleaved GALC can 
provide a measure of lysosomal delivery of wild-
type (WT) and mutant forms of GALC. Cell lysates 
from GALC missense mutations that are not 
secreted into the conditioned media, such as 
R515H and T513M (Fig. 1A), have no detectable 
30-kDa cleavage product (Fig. 2C) consistent with 
these proteins being trapped in the ER due to 
misfolding and therefore are not delivered to 
lysosomes. Missense mutations that are secreted 
into the conditioned media, such as R380W and 
E215K, show reduced but still detectable levels of 
GALC cleavage product. 
Non-secreting, unprocessed missense 
mutations of GALC are trapped in the ER 
Absence of GALC in the conditioned media and the 
lack of cleaved product in cell lysates together 
provide compelling evidence that a particular GALC 
variant causes disease due to compromised protein 
folding and is thus retained in the ER. However, 
both these measures are indirect and so several 
GALC variants were further tested by direct 
monitoring of their cellular localization. GALC 
variants were expressed in HeLa cells and detected 
by immunofluorescence microscopy using 
monoclonal antibodies raised against full-length 
human GALC and compared with markers for the 
ER (calreticulin, calnexin and REEP5) and 
lysosome (cathepsin D). Immunofluorescence 
microscopy clearly identifies that WT GALC co-
localizes with cathepsin D identifying its correct 
trafficking to lysosomes (Fig. 3A). Missense 
mutations that were shown to inhibit secretion of 
GALC and prevent normal processing in the 
lysosome were tested for their cellular localization 
(Fig. 3B, Fig. S1 and S2). T513M and L618S show 
clear reticular staining consistent with ER 
architecture and very poor co-localization with the 
lysosomal marker (Fig. 3C). The co-localization of 
these variants with the ER markers confirmed their 
ER localization (Fig. 3B, 3C, Fig. S1). Additional 
missense mutations I583S, R515H and Y319C 
were also identified to co-localize with the ER 
markers calreticulin and calnexin (Fig. S2).  
Missense mutations of GALC that are secreted by 
cells and show cleavage consistent with lysosomal 
localization were also tested for their cellular 
localization. The residue R380 has been shown by 
us previously to be critical for enzyme activity as it 
directly binds substrate in the active site (3, 21). In 
this case, we would expect this mutation not to 
interfere with folding and to traffic to the lysosome 
where the disease-causing defect is primarily 
catalytic. In agreement with this, immunostaining of 
the R380W mutant identifies that it co-localizes with 




lysosomes to the same extent as WT GALC (Fig. 
4A and 4C). GALC containing the missense 
mutation E215K can be secreted into the media and 
shows cellular localization similar to WT GALC (Fig. 
4B). Consistent with the secretion profile, E215K is 
not primarily co-localized with the ER marker 
calreticulin suggesting that the disease mechanism 
in this case is not due to a misfolding defect (Fig. 
4C).  
N279T introduces a new glycosylation site that 
interferes with protein trafficking 
The missense mutation N279T is detected in 
conditioned media but runs at a slightly higher 
molecular weight compared with WT and other 
missense variants (Fig. 1A). Analysis of the 
sequence surrounding this residue identifies that 
this mutation introduces a new consensus site for 
N-linked glycosylation of residue N277 (Fig. 5A). 
This additional glycan can be detected in cell 
lysates and can be abolished by introduction of the 
second mutation N277D to block glycosylation of 
this residue (Fig. 5B). Unlike other secreted GALC 
variants, N279T does not localize to lysosomes 
(Fig. 5C). Introduction of an additional glycan at 
residue N277 would be predicted to destabilize the 
fold of this GALC variant as this residue is deeply 
buried at the interface between two domains (Fig. 
5D). Although introduction of the second mutation 
N277D blocks addition of the extra glycan, the 
double mutant does not rescue trafficking to the 
lysosome (Fig. 5C). Despite the conservative nature 
of the introduced N277D mutation, this change 
alone causes misfolding of GALC such that it is not 
trafficked to the lysosome (Fig. 5C). The 
observation that N279T can be secreted but not 
enter the endocytic pathway suggests that some 
protein can escape ER-associated quality control 
but is defective for binding to the mannose 6-
phosphate receptor. To test this, an uptake assay 
was carried out whereby conditioned media 
containing the N279T variant was applied to 
untransfected cells in a manner similar to that 
shown for WT GALC (Fig. 5E). Unlike WT GALC, 
the N279T variant cannot be taken up by cells 
suggesting that the additional glycan interferes with 
endocytosis. 
The polymorphism at position 546 has subtle 
effects on enzyme activity, stability and 
trafficking 
The missense mutations described here have been 
tested in the most common polymorphic 
background I546. However the polymorphism T546 
has been reported to be present within the 
population at allele frequency of 40-45% (22). 
Clinical assays for GALC activity in peripheral blood 
have suggested that the T546 variant has half the 
activity of the I546 variant, contributing to the highly 
variable “normal” activity levels within the general 
population (22-24). In order to test the effect of this 
polymorphism on GALC activity we generated 
stable expression constructs of each of these 
polymorphisms and selected high-yield clones in 
order to purify milligram quantities of GALC for 
steady-state kinetic studies (Fig. 6A and Table S2). 
Surprisingly, the two variants do not have 
significantly different catalytic properties in vitro: 
T546 has 89% activity of I546 suggesting that the 
observed differences in activity from blood samples 
may be due to differential stability, expression or 
trafficking in cells. Thermal denaturation of secreted 
GALC monitored by differential scanning fluorimetry 
revealed a subtle destabilization of the T546 variant 
in vitro (Fig. 6B; Tm, I546 = 51.8 ± 0.2 °C vs Tm, 
T546 = 50.6 ± 0.2 °C). To determine whether this 
degree of destabilization was sufficient to impair 
trafficking of GALC the presence of T546 in 
conditioned media was monitored. Interestingly, this 
variant was not detectable in the media suggesting 
it is trapped in the ER (Fig. 7A). However, if this 
polymorphism completely blocked trafficking of 
GALC to the lysosome this would represent a 
disease-causing mutation. Cellular localization of 
T546 by immunofluorescence microscopy confirms 
that although this variant is not detected in 
conditioned media it can be trafficked to the 
lysosome (Fig. 7B). The combination of multiple, 
subtle deleterious effects on activity, stabilization 
and trafficking of the T546 variant may explain the 
observed reduction in enzyme activity from 
peripheral blood samples.  
Although the I546T polymorphism on its own has 
only subtle effects on GALC function, when 
combined with additional missense mutations the 
cumulative effects can become severe. Indeed, it 
has been suggested previously that certain 
mutations are only disease-causing in specific 
polymorphic backgrounds (25). The G270D variant 
is responsible for a late-onset form of Krabbe 
disease and is usually found in cis with the I546T 
polymorphism (26). In the I546 background, the 
G270D variant possesses WT levels of protein 
secreted in to the media and WT localization to 
lysosomes (Fig. 7A, C). However, in the T546 
background, the G270D mutation is severely 
compromised in its cellular trafficking and is not 
localized to lysosomes (Fig. 7A and 7C, Fig. S3). 
The cumulative effect of these two sequence 
variations is not due to a single localized structural 
perturbation as the two residues, G270 and I546, lie 
in distant parts of the GALC structure (Fig. 7D). 
Specifically, G270 is situated near the disulphide 
bond that stabilizes a critical active-site loop 
structure while residue 546 lies in the C-terminal 
lectin domain.  
The missense mutation Y551S causes infantile 
Krabbe disease and has been identified in the T546 
polymorphic background (26). These two residues 
are much closer to each other in the GALC 
structure and so might be expected to have a 
severe cumulative effect on folding (Fig. 7D). 
However, the secretion profile of this mutation 
shows that even in the I546 background the Y551S 
mutation has a severe detrimental effect on protein 
folding and secretion (Fig. 7A). In agreement with 
this, the Y551S variant in both polymorphic 
backgrounds does not traffic correctly to lysosomes 
(Fig. 7C and Fig. S3).  
 





In order to better understand the underlying 
molecular mechanisms causing GALC dysfunction 
in Krabbe disease, clinically-relevant variants of 
GALC were expressed in cells and monitored for 
their capacity to traffic beyond the ER-TGN and to 
localize to their site of action in lysosomes. Using a 
series of cell-based assays we have identified the 
underlying pathogenesis for a number of these 
variants. Initial screening of the secretion profile of 
GALC variants provides a good first indication of 
whether a mutation may result in protein misfolding. 
The protein quality control pathways present in the 
ER should result in the retention and degradation of 
misfolded protein. In this case misfolded GALC will 
not traffic beyond the ER and thus will not be 
detected in the conditioned media. Using this 
approach we identified seven variants (Y319C, 
L618S, G41S, T513M, I583S, R515H and R63H) 
that are likely to cause disease due to protein 
misfolding. Another subset of GALC variants 
(R380W, E215K, N279T, P302R and R380L) were 
present in the conditioned media identifying that the 
underlying pathology in these cases is not primarily 
protein misfolding. A further assay was used to 
monitor trafficking beyond the ER-TGN by exploiting 
the observation that upon delivery of GALC to 
lysosomes, a 30-kDa cleavage product can be 
identified following SDS-PAGE and immunoblotting. 
In support of their predicted defect in protein folding, 
two of the missense mutations identified as non-
secretors, R515H and T513M, were not processed 
into this smaller fragment. Consistent with the 
secretion assay, two of the secreted variants 
(R380W and E215K) were shown to undergo 
proteolytic processing similar to that seen for WT 
GALC.  
Lack of protein secretion and the inability to be 
processed into the 50- and 30-kDa fragments are 
indicative of a misfolded GALC variant suggesting it 
is retained in the ER. To further test this, the cellular 
localization of GALC variants was directly monitored 
by immunofluorescence microscopy using newly-
generated, specific monoclonal antibodies raised 
against full-length human GALC protein. Using this 
approach, the GALC variants, T513M, L618S, 
Y319C, I583S and R515H were not localized to 
lysosomes and were trapped in the ER (Fig. 3, Fig. 
S1 and S2). These GALC variants can be classified 
as protein misfolding mutants due to their lack of 
secretion, inability to be proteolytically processed 
and their retention in the ER. 
Those disease variants that do not result in 
significant misfolding, based on their secretion, 
processing and cellular localization, fall into a 
number of categories. The residue R380 has been 
shown by us previously to play a critical role in the 
catalytic processing of substrates (3, 21). In support 
of this, R380W and R380L are secreted similarly to 
WT GALC and R380W was shown to localize to 
lysosomes. E215K was also normally secreted and 
trafficked within the cell but is not likely to be 
catalytically defective as this mutation does not lie 
near the enzyme active site. This residue is on the 
surface of GALC and the charge inversion caused 
by this mutation may interfere with important 
interactions with partner proteins such as saposin 
A. The mutation N279T was shown to introduce a 
new glycosylation consensus sequence resulting in 
the addition of an N-linked glycan to residue N277. 
This variant is capable of being secreted by cells 
and so can pass ER quality control but is unable to 
be taken up by cells or traffic to lysosomes 
suggesting that the new glycan may interfere with 
endocytosis by altering binding to the M6PR. 
A number of polymorphisms have been identified in 
the GALC gene and have been shown to have a 
negative effect on GALC activity. In this study we 
produced both the I546 and T546 variants of GALC 
and compared their activity and stability in vitro. 
Surprisingly this polymorphism has only a subtle 
effect on GALC enzyme kinetics and thermal 
stability but did have a significant effect on its 
trafficking beyond the ER-TGN. This suggests that 
the lower activity reported for this polymorphism is a 
reflection of its reduced trafficking rather than its 
inability to process substrate. It has been shown 
previously that the polymorphic background that a 
missense mutation occurs in can critically change 
the disease pathogenesis (25, 27). In agreement 
with this, we show that G270D only results in 
protein misfolding, as measured by ER co-
localization, when present in the T546 background. 
Thus in this case, it is the combination of two subtle 
defects that results in disease. However, despite 
the Y551S variant only being identified in the T546 
background, it results in protein misfolding in both 
polymorphic backgrounds identifying that this 
mutation alone is sufficient to cause significant 
protein misfolding.   
The availability of structural data for GALC allows 
prediction of the functional effects of missense 
mutations: the greater proportion of a side chain 
that is buried in the structure the greater the 
likelihood that a mutation of that residue will disrupt 
the fold (3). These predictions can now be 
compared with the functional effects identified here 
(Table S3). The side chains for residues G41, Y319, 
T513, I583 and L618 are completely buried in the 
structure suggesting that mutation of these would 
result in misfolding and in agreement with this 
prediction, all were not secreted by cells and/or 
were localized to the ER. However, G270 is also 
completely buried but the G270D variant is only 
localized to the ER when present in the T546 
background. The side chains of R63, R515 and 
Y551 are also primarily (~80%) buried in the 
structure and are here identified as non-secretors 
identifying that even only partially buried residues 
can significantly disrupt folding. However, based on 
buried surface area, P302 would also fall into this 
category but is shown here to be secreted in 
disagreement with the structure-based prediction. 
E215 and R380 are relatively exposed on the 
surface of GALC (only 57% and 48% buried) 
suggesting that residues that are <60% buried are 
unlikely to result in misfolding. Based on this 
analysis, the structure provides a good molecular 
framework for making predictions but verification in 
cell-based assays is still required. 




In this study we have used three different assays to 
monitor trafficking defects in GALC variants. Each 
assay has different levels of complexity and 
sensitivity allowing a confidence level to be 
associated with the designation of the molecular 
defect caused by a specific mutation. The 
importance of using multiple assays is best 
highlighted by those variants that have subtle 
effects such as the I546T polymorphism. Although 
this polymorphism is not disease-causing, in our 
secretion assay it is not detectable suggesting that 
this assay alone is not sufficiently sensitive to 
distinguish subtle GALC defects. However, 
monitoring cellular localization by immunostaining 
appears to be much more sensitive as in this case 
the polymorphic variant can be localized to 
lysosomes. Thus although the secretion assay is a 
fast and convenient readout it is important that 
conclusions regarding the underlying pathogenesis 
of subtle variants be confirmed using the more 
sensitive co-localization assay.  
Extrapolation from disease mechanism to disease 
severity remains highly challenging. The disease-
causing variant L618S has a complex effect in 
patients and has been identified in patients with age 
of onset ranging from late-infantile to adult (28-30). 
This variation in disease severity is likely influenced 
by many factors including the polymorphic 
background and compound heterozygosity both of 
which have been documented for this variant. 
Recently, Shin et al also showed that L618S is 
severely compromised in its ability to be correctly 
processed into the 50- and 30-kDa fragments 
supporting a defect in folding (31). However, unlike 
our localization studies identifying L618S as trapped 
in the ER, Shin et al found some evidence that this 
variant co-stains with LAMP2 suggesting it 
maintains some capacity to be delivered to late 
endosomes/lysosomes. For this reason one must 
be cautious to assign degree of disease severity 
based on these assays but should instead use the 
identification of the nature of the defect as a critical 
factor for subsequent therapeutic targeting. 
Mutations that cause misfolding, giving rise to lack 
of secretion, processing and primarily ER co-
localization, may be good targets for 
pharmacological chaperone therapies while those 
that retain significant capacity for correct trafficking 
and processing will require future enzyme 
replacement approaches. However, the extent of 
misfolding caused by specific mutations will alter 
the effectiveness of pharmacological chaperones. 
Specifically, the misfolding caused by some 
mutations may prove too severe to respond to these 
approaches and will therefore require enzyme 
replacement strategies. 
Studies in related lysosomal storage disorders have 
examined the effects of missense mutations on 
enzyme processing and trafficking. Retention of 
misfolded protein in the ER is an important factor in 
specific variants that cause Gaucher disease (32-
35), Pompe disease (36) and GM1 gangliosidosis 
(37). In several cases, this insight has been used to 
examine if pharmacological chaperones, ERAD 
inhibitors and proteostasis regulators can rescue 
these misfolded variants and restore trafficking to 
the lysosome. Although these studies have 
provided some potential leads for therapeutic 
development, they have also highlighted that these 
approaches are often only successful with a limited 
subset of mutations potentially due to the severity of 
the misfolding defect (mentioned above). One of the 
current limitations in drug development for Krabbe 
disease is the lack of reliable high-throughput (HT) 
approaches for the screening of new therapeutics 
against the wide range of mutations present in the 
patient population. Although activity measurements 
can be carried out in a HT manner (38), previous 
work has shown that GALC activity does not 
correlate well with disease severity and may not 
provide a good measure for treatment efficacy (25, 
31). One of the primary reasons for this may be 
attributed to the fact that the activity assays are 
often conducted on whole cell lysates and so 
cannot distinguish between protein that is localized 
in the ER or the endocytic pathway leaving the 
question as to whether the active protein is still 
mislocalized unanswered. Recent work measuring 
th  activity of samples enriched for the lysosomal 
fraction show a better correlation with disease 
severity providing a good first step towards more 
reliable activity measurements (31). Future 
development of the assays described here into a 
HT format would provide a complementary readout 
to these activity assays and confirm those 
conditions where GALC is successfully trafficked 









Materials and Methods  
 
Cloning and mutagenesis of human GALC 
constructs. For large-scale protein expression in 
mammalian cells wild-type human GALC (hGALC) 
polymorphisms I546 and T546 were cloned into 
pSecTag2B vector with an N-terminal His6 tag and 
stable HEK293T cell lines were established and 
cultured as described previously (3). For transient 
expression of mutants in mammalian tissue culture 
mutant hGALC constructs were generated in the 
pSecTag2b vector by Quikchange site directed 
mutagenesis of wild type hGALC in either the I546 
or T546 background (as indicated). Constructs were 
then sub-cloned into the pHLsec vector resulting in 
removal of the His tag and addition of a C-terminal 
FLAG epitope tag.  
 
Expression and purification of human GALC 
protein. Large-scale expression and IMAC-affinity 
purification of hGALC proteins from HEK293T cells 
for antibody (Ab) generation, activity assays and 
thermal denaturation experiments was carried out 
as described previously for the equivalent mouse 
GALC constructs (21, 39).  
 
Monoclonal antibody generation. Monoclonal 
mouse anti-human GALC antibodies were raised 
against full-length secreted human GALC protein. 
Mice were immunized subcutaniosly 2 times with 25 
µg of purified human GALC, mixed with GERBU® 
adjuvant. Three days before the fusion, the mice 
received an i.v. injection with 10 µg of antigen 
together with adrenalin. Spleen cells and SP2 
myeloma cells were used for fusion. Positive clones 
were selected and cloned by repeated screening 
against the GALC protein by ELISA. The 
performance and specificity of several antibody 
clones were validated by Western blot and 
immunofluorescence microscopy against 
transfected cells. 
 
Cell culture. HEK293T and HeLa cells were 
maintained in Dulbecco’s Modified Eagle Medium 
supplemented with 10% foetal bovine serum, 50 
units/ml Penicillin, 50 µg/ml Streptomycin and 4 mM 
L-glutamine.  Cells were maintained at 37°C in 
humidified air with 5% CO2. HEK293T cells used for 
immunoblot studies were grown in Freestyle 293 
expression medium and transiently transfected 
using Lipofectamine-2000 transfection reagent.  
HeLa cells used for immunostaining were 
transiently transfected at 40% confluence using the 
TransIT-HeLa Monster transfection reagent. For 
GALC uptake assays, serum free conditioned 
media from transfected or untransfected cells was 
harvested and filtered 72 hours post-transfection 
and then applied to untransfected cells for 48 hours. 
Cells were lysed in 1% Triton X-100 and subjected 
to immunoprecipitation using monoclonal mouse 
anti-GALC antibody in the presence of protein A 
sepharose beads. GALC cellular uptake was 
detected by immunoblot, as described below.   
 
Immunoblotting and immunoprecipitation of 
GALC. Secreted protein was detected from 
conditioned media harvested 72 hours post-
transfection. Cells were lysed in either 1% Triton X-
100 or 1% SDS in Tris-buffered saline (TBS, 20 mM 
Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA)  
in the presence of 10 mM N-ethylmaleimide (NEM), 
1 mM phenylmethylsulfonyl fluoride (PMSF) and 
protease inhibitors. Where appropriate, protein 
concentration was quantified via BCA assay. For 
immunoprecipitation, 1000 µg cell lysate was 
precleared using IgG/protein A-sepharose beads. 
Pre-cleared lysate was incubated with anti-FLAG or 
anti-GALC antibodies in the presence of A-
sepharose beads and washed in TBS 
supplemented with 0.1% Triton X-100. All samples 
were denatured and reduced in SDS loading buffer 
containing 20 mM DTT prior to SDS-PAGE 
separation. For immunoblot studies, proteins were 
transferred to methanol-activated Immobilon-FL 
PVDF membrane. After blocking, membranes were 
incubated with primary antibody followed by 
incubation with infrared fluorophore–conjugated 
secondary antibody. Immuno-reactive bands were 
visualised with an Odyssey infrared imager (LI-COR 
Biosciences).  
 
Confocal immunofluorescence microscopy. 
Cells were grown on glass coverslips, washed with 
PBS and fixed in 4% PFA. Fixed cells were washed 
in PBS, quenched with 15mM glycine and 
permeabilised in 0.1% saponin in PBS. Fixed cells 
were blocked in 1% BSA, 0.01% saponin in PBS 
before incubation with primary antibody diluted in 
1% BSA with 0.01% saponin followed by 
fluorescently-conjugated secondary antibody. 
Coverslips were mounted onto slides using 
mounting medium with DAPI (Prolong Antifade, 
Invitrogen Molecular Probes). Images were 
acquired on a Zeiss LSM880 confocal microscope 
with Zeiss zen software. To analyse co-localization, 
intensities were measured for ≥20 individual cells 
from ≥3 independent experiments and Pearson’s 
correlation coefficients were calculated using the 
Volocity 5.2 software (Perkin Elmer). Automatic 
Costes thresholds were applied to all images (40). 
Significance was calculated using two-tailed t-tests 
implemented in Prism5 (Graphpad), error bars 
represent SEM. Endogenous GALC is not 
detectable by immunostaining of untransfected 
HeLa cells (Fig. S4A and B). HeLa cells transfected 
with the N-terminally His-tagged construct of GALC 
show equivalent cellular localization as the C-
terminally FLAG-tagged construct (Fig. S4).   
 
Antibodies. The antibodies used for 
immunostaining were: monoclonal mouse anti-
GALC clone mAb6 (described above), polyclonal 
rabbit anti-cathepsin D (Calbiochem), polyclonal 
rabbit calreticulin (Pierce), polyclonal rabbit calnexin 
(Abcam), polyclonal rabbit anti-REEP5 
(proteintech), polyclonal goat AlexaFluor488-
conjugated anti-mouse IgG (Life technologies) and 
polyclonal goat AlexaFluor555-conjugated anti-
rabbit IgG (Life technologies). Antibodies used for 
immunoblotting were: monoclonal mouse anti-FLAG 
(Sigma), monoclonal mouse anti-GALC clones 
mAb1 and mAb2 (described above), polyclonal 
rabbit anti-GALC (Abcam), polyclonal rabbit anti-




actin (Sigma), polyclonal goat IRdye680-conjugated 
anti-rabbit IgG (LiCor) and polyclonal goat 
IRdye800-conjugated anti-mouse IgG (LiCor). 
 
Deglycosylation of GALC. Conditioned media and 
cells lysed in 1% SDS (as described above) were 
denatured at 100°C for 10 mins and were either 
subjected to EndoH or PngaseF treatment (NEB) 
for 4 hours at 37°C.  
 
Enzyme activity assays. Activity assays were 
carried out as described previously (21). In brief, 
activity assays were carried out at 37°C using 
purified hGALC in 20 mM sodium acetate, 150 mM 
NaCl, 0.1% v/v NP-40, pH 4.6 and chromogenic 
substrate 4-nitrophenyl-β-D-galactopyranoside 
(4NβDG). Product 4-nitrophenol was monitored by 
absorbance at 410nm following addition of stopping 
buffer (360 mM NaOH, 280 mM glycine, pH 10.6). 
Km and Vmax were obtained from plots of initial 
velocity against substrate concentration by non-
linear curve-fitting to the Michaelis-Menten equation 
using Prism5 (GraphPad). kcat was determined as 
the gradient of the linear plot of Vmax against 
enzyme concentration. 
 
Differential scanning fluorimetry. DSF 
experiments were carried out as described 
previously (39). In brief, 5 µg of purified hGALC in 
PBS, pH 7.4 was combined with 5x SyPRO Orange 
dye prior to thermal denaturation performed using a 
Bio-Rad MiniOpticon RT-PCR thermal cycler. The 
melting temperature (Tm) was the inflexion point of 
the sigmoidal curve obtained by curve fitting using 
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Figure 1. Missense mutations alter GALC secretion from cells. HEK293T cells were transiently transfected 
with FLAG-tagged wild-type (WT) GALC and a panel of clinically relevant Krabbe disease mutations. Conditioned 
media was harvested at 72 hours and cells lysed in 1% SDS followed by SDS-PAGE and immunoblotting. A) 
Secreted and total GALC expression were detected by Western blot using an anti-FLAG antibody. Actin served 
as a loading control. B) Conditioned media and cell lysates were digested with either EndoH or with PNGaseF 
before immunoblotting with anti-FLAG-to detect GALC. 
 
Figure 2. Proteolytic cleavage of WT and mutant GALC. A) Protein lysates from either untransfected 
HEK293T cells or from cells transfected with WT GALC were subjected to immunoprecipitation with monoclonal 
antibodies against full-length human GALC (mAb1 and mAb2) or the FLAG epitope tag. GALC was detected by 
Western blot using a polyclonal rabbit GALC antibody, cleavage product at ~30-kDa is marked with an asterisk. 
B) Conditioned media (CM) from HEK293T cells transfected with WT GALC contains full-length GALC (lane 1). 
GALC-containing CM (+) and CM from untransfected cells (-) was harvested after 72 hours and applied to 
untransfected HEK293T cells for 48 hours. Treated cells were subjected to immunoprecipitation using the GALC 
monoclonal antibody mAb2 and detected as in A. C) HEK293T cells were transiently transfected with WT GALC 
and Krabbe mutations R380W, E215K, R515H and T513M and immunoprecipitated using the mAb2 antibody and 
detected as in A.   
 
Figure 3. Missense mutations of GALC that interfere with secretion and cleavage are trapped in the ER. 
Representative confocal microscopy images of HeLa cells transiently transfected with either WT GALC (A), or the 
Krabbe mutations T513M and L618S (B). Cells were plated onto glass coverslips, fixed and immunostained using 
monoclonal antibody against GALC (green), the lysosomal marker cathepsin D (red) or the ER marker calreticulin 
(red). Nuclei were stained with DNA-binding dye, DAPI (blue). Scale bar 10 µm. (C) To quantify co-localization, 
Pearson’s correlation coefficients were calculated for each variant with both cathepsin D and calreticulin. Mean ± 
SEM for at least 20 individual cells from ≥3 independent experiments are shown. ***p= < 0.0001, calculated using 
a two-tailed unpaired t-test. 
 
Figure 4. Missense mutations R380W and E215K are trafficked to the lysosome. Representative confocal 
microscopy images of HeLa cells transiently transfected with Krabbe mutations R380W (A) and E215K (B). 
Transfected cells were plated onto glass coverslips, fixed and immunostained for GALC (green), the lysosomal 
marker cathepsin D (red) or the ER marker calreticulin (red). Scale bar 10 µm. (C) Pearson’s correlation 
coefficients were calculated for each of the mutations with both cathepsin D and calreticulin.  Mean ± SEM for at 
least 20 individual cells from ≥3 independent experiments are shown. **p= <0.005, *p= <0.05, ns = not 
significant, calculated using a two-tailed unpaired t-test. 
 
Figure 5. N279T is a hyperglycosylation mutant with defective trafficking. A) Protein sequence of WT and 
N279T GALC illustrating the introduction of a new consensus glycosylation site (NXT). B) HEK293T cells 
transiently transfected with WT GALC, Krabbe mutation N279T or double mutant N279T/N277D were lysed with 
1% SDS, separated by SDS-PAGE and immunoblotted. Total GALC expression was analysed by Western blot 
against the FLAG epitope tag. C) HeLa cells were transiently transfected with Krabbe mutation N279T, the 
double mutation N279T/N277D or N277D alone, plated and fixed on glass coverslips and immunostained for 
GALC (green) and the lysosomal marker cathepsin D (red). Scale bar 10 µm. D) The newly glycosylated residue, 
N277, is highlighted on the structure of GALC (PDB ID: 3ZR5). The structure is coloured according to domain 
(TIM barrel in blue, β-sandwich in red and lectin domain in green). Zoomed view (inset) shows the N277 
sidechain as sticks. E) Conditioned media from either untransfected HEK293T cells (-) or cells transfected with 
WT or Krabbe mutation N279T (+) was harvested after 72 hours and applied to untransfected HEK293T cells for 
48 hours. Treated cells were subjected to immunoprecipitation using the GALC monoclonal antibody mAb2. 
GALC was detected by Western blot using a polyclonal rabbit GALC antibody. 
 
Figure 6. Effect of the I546T polymorphism on enzyme activity and stability. A) Michaelis–Menten plots of 
initial velocity vs. substrate concentration at GALC concentrations of 0.420 nM (○), 0.842, (◇), 1.68, (▼), 3.37 
nM, (▲), 6.73 nM, (□), and 13.4 nM (●). (Inset) Plot of Vmaxobs vs. GALC concentration showing kcat as the 
gradient (11.9 s
−1
 for I546 and 10.6 s
-1
 for T546). Experiments were performed in triplicate and SEM error bars 
are shown. B) Differential scanning fluorimetry of GALC polymorphisms I546 (■) and T546 (○) demonstrate 
similar thermal denaturation profiles. 
 




Figure 7. Polymorphic background alters the trafficking of some missense mutations. A) HEK293T cells 
were transiently transfected with WT GALC (I546), T546, Y551S-I546, Y551S-T546, G270D-I546, G270D-T546. 
Conditioned media was harvested at 72 hours and cells lysed in 1% SDS followed by SDS-PAGE and 
immunoblotting. Secreted and total GALC expression was detected by Western blot against the FLAG epitope 
tag and loading analysed by blotting against actin. B) Representative confocal microscopy images of HeLa cells 
transiently transfected with WT GALC containing the T546 polymorphism. Cells were plated onto glass 
coverslips, fixed and immunostained for GALC (green), the lysosomal marker cathepsin D (red). Nuclei were 
stained with DNA-binding dye, DAPI (blue). Scale bar 10 µm.To quantify co-localization Pearson’s correlation 
coefficients were calculated for cathepsin D. Mean ± SEM for at least 20 individual cells from ≥3 independent 
experiments are shown. C) Equivalent confocal microscopy images as in panel B for Y551S-I546, Y551S-T546, 
G270D-I546 and G270D-T546. D) The positions of I546T, G270D and Y551S are highlighted on the structure of 
GALC (PDB ID: 3ZR5). The structure is coloured as in Fig 5. For each variant, the zoomed view (inset) shows the 
relevant side chain as sticks and the surrounding region of the structure that would be affected by the mutation. 
The single disulphide bond (yellow) present in GALC is illustrated as spheres. 
  






Supplementary Table S1: Missense mutations of GALC described in the text. 
 This table is first associated with Figure 1 but is relevant to the whole paper and describes the alternative 
numbering used in the literature allowing for greater clarity when comparing with other published data 
using this numbering scheme. 
 
Supplementary Table S2: Enzyme activity of WT GALC I546 and the T546 polymorphism. 
 This table is associated with Figure 6 and provides the details of the enzyme activity values Km, Vmax and 
kcat calculated from the data in Fig. 6. 
 
Supplementary Table S3: Proportion of side chain buried in the structure, prediction and identified defect 
 This table is associated with the Discussion and summarises the correlation between the buried surface 
area of a side chain as calculated from the structure and the predicted effect this would have on the 
protein compared with the molecular mechanism identified in this work. 
 
Supplementary Figure S1: Co-localization of T513M and L618S missense mutations with additional ER markers. 
 This figure provides additional representative confocal images of T513M and L618S co-localized with the 
ER markers calnexin and REEP5. These images are associated with Figure 3. 
 
Supplementary Figure S2: Co-localization of additional missense mutations of GALC with ER markers.  
 This figure provides representative confocal images of additional missense mutations I583S, R515H and 
Y319C showing co-localization with the ER markers calreticulin and calnexin. These images are 
associated with Figure 3. 
 
Supplementary Figure S3: Effect of polymorphic background on trafficking of G270D and Y551S. 
 This figure provides additional representative confocal images of G270D and Y551S in both polymorphic 
backgrounds co-localized with the ER marker REEP5. These images are associated with Figure 7. 
 
Supplementary Figure S4. Representative confocal images from untransfected HeLa cells and cells expressing 
N-terminally tagged GALC constructs. 
 This figure provides evidence that endogenous GALC is not detectable in untransfected HeLa cells and 
that a construct of GALC possessing a tag at the N-terminus displays similar cellular localization as the C-
terminally tagged construct. This figure is associated with the Materials and Methods section. 
 
 





Figure 1. Missense mutations alter GALC secretion from cells. HEK293T cells were transiently transfected 
with FLAG-tagged wild-type (WT) GALC and a panel of clinically relevant Krabbe disease mutations. 
Conditioned media was harvested at 72 hours and cells lysed in 1% SDS followed by SDS-PAGE and 
immunoblotting. A) Secreted and total GALC expression were detect d by Western blot using an anti-FLAG 
antibody. Actin served as a loading control. B) Conditioned media and cell lysates were digested with either 
EndoH or with PNGaseF before immunoblotting with anti-FLAG-to detect GALC.  
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Figure 2. Proteolytic cleavage of WT and mutant GALC. A) Protein lysates from either untransfected 
HEK293T cells or from cells transfected with WT GALC were subjected to immunoprecipitation with 
monoclonal antibodies against full-length human GALC (mAb1 and mAb2) or the FLAG epitope tag. GALC 
was detected by Western blot using a polyclonal rabbit GALC antibody, cleavage product at ~30-kDa is 
marked with an asterisk. B) Conditioned media (CM) from HEK293T cells transfected with WT GALC contains 
full-length GALC (lane 1). GALC-containing CM (+) and CM from untransfected cells (-) was harvested after 
72 hours and applied to untransfected HEK293T cells for 48 hours. Treated cells were subjected to 
immunoprecipitation using the GALC monoclonal antibody mAb2 and detected as in A. C) HEK293T cells 
were transiently transfected with WT GALC and Krabbe mutations R380W, E215K, R515H and T513M and 
immunoprecipitated using the mAb2 antibody and detected as in A.  
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Figure 3. Missense mutations of GALC that interfere with secretion and cleavage are trapped in the ER. 
Representative confocal microscopy images of HeLa cells transiently transfected with either WT GALC (A), or 
the Krabbe mutations T513M and L618S (B). Cells were plated onto glass coverslips, fixed and 
immunostained using monoclonal antibody against GALC (green), the lysosomal marker cathepsin D (red) or 
the ER marker calreticulin (red). Nuclei were stained with DNA-binding dye, DAPI (blue). Scale bar 10 µm. 
(C) To quantify co-localization, Pearson’s correlation coefficients were calculated for each variant with both 
cathepsin D and calreticulin. Mean ± SEM for at least 20 individual cells from ≥3 independent experiments 
are shown. ***p= < 0.0001, calculated using a two-tailed unpaired t-test.  
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Figure 4. Missense mutations R380W and E215K are trafficked to the lysosome. Representative confocal 
microscopy images of HeLa cells transiently transfected with Krabbe mutations R380W (A) and E215K (B). 
Transfected cells were plated onto glass coverslips, fixed and immunostained for GALC (green), the 
lysosomal marker cathepsin D (red) or the ER marker calreticulin (red). Scale bar 10 µm. (C) Pearson’s 
correlation coefficients were calculated for each of the mutations with both cathepsin D and 
calreticulin.  Mean ± SEM for at least 20 individual cells from ≥3 independent experiments are shown. **p= 
<0.005, *p= <0.05, ns = not significant, calculated using a two-tailed unpaired t-test.  
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Figure 5. N279T is a hyperglycosylation mutant with defective trafficking. A) Protein sequence of WT and 
N279T GALC illustrating the introduction of a new consensus glycosylation site (NXT). B) HEK293T cells 
transiently transfected with WT GALC, Krabbe mutation N279T or double mutant N279T/N277D were lysed 
with 1% SDS, separated by SDS-PAGE and immunoblotted. Total GALC expression was analysed by Western 
blot against the FLAG epitope tag. C) HeLa cells were transiently transfected with Krabbe mutation N279T, 
the double mutation N279T/N277D or N277D alone, plated and fixed on glass coverslips and immunostained 
for GALC (green) and the lysosomal marker cathepsin D (red). Scale bar 10 µm. D) The newly glycosylated 
residue, N277, is highlighted on the structure of GALC (PDB ID: 3ZR5). The structure is coloured according 
to domain (TIM barrel in blue, β-sandwich in red and lectin domain in green). Zoomed view (inset) shows 
the N277 sidechain as sticks. E) Conditioned media from either untransfected HEK293T cells (-) or cells 
transfected with WT or Krabbe mutation N279T (+) was harvested after 72 hours and applied to 
untransfected HEK293T cells for 48 hours. Treated cells were subjected to immunoprecipitation using the 
GALC monoclonal antibody mAb2. GALC was detected by Western blot using a polyclonal rabbit GALC 
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antibody.  
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Figure 6. Effect of the I546T polymorphism on enzyme activity and stability. A) Michaelis–Menten plots of 
initial velocity vs. substrate concentration at GALC concentrations of 0.420 nM (○), 0.842, (◇), 1.68, (▼), 
3.37 nM, (▲), 6.73 nM, (□), and 13.4 nM (●). (Inset) Plot of Vmaxobs vs. GALC concentration showing kcat 
as the gradient (11.9 s−1 for I546 and 10.6 s-1 for T546). Experiments were performed in triplicate and 
SEM error bars are shown. B) Differential scanning fluorimetry of GALC polymorphisms I546 (■) and T546 
(○) demonstrate similar thermal denaturation profiles.  
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Figure 7. Polymorphic background alters the trafficking of some missense mutations. A) HEK293T cells were 
transiently transfected with WT GALC (I546), T546, Y551S-I546, Y551S-T546, G270D-I546, G270D-T546. 
Conditioned media was harvested at 72 hours and cells lysed in 1% SDS followed by SDS-PAGE and 
immunoblotting. Secreted and total GALC expression was detected by Western blot against the FLAG epitope 
tag and loading analysed by blotting against actin. B) Representative confocal microscopy images of HeLa 
cells transiently transfected with WT GALC containing the T546 polymorphism. Cells were plated onto glass 
coverslips, fixed and immunostained for GALC (green), the lysosomal marker cathepsin D (red). Nuclei were 
stained with DNA-binding dye, DAPI (blue). Scale bar 10 µm.To quantify co-localization Pearson’s correlation 
coefficients were calculated for cathepsin D. Mean ± SEM for at least 20 individual cells from ≥3 
independent experiments are shown. C) Equivalent confocal microscopy images as in panel B for Y551S-
I546, Y551S-T546, G270D-I546 and G270D-T546. D) The positions of I546T, G270D and Y551S are 
highlighted on the structure of GALC (PDB ID: 3ZR5). The structure is coloured as in Fig 5. For each variant, 
the zoomed view (inset) shows the relevant side chain as sticks and the surrounding region of the structure 
that would be affected by the mutation. The single disulphide bond (yellow) present in GALC is illustrated as 
spheres.  
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* The first start site in exon 1 is used for numbering in Uniprot entry P54803 and is has also been adopted by 
some publications. For clarity, these designations are also provided. 




















Table S2. Enzyme activity of WT GALC I546 and the T546 polymorphism 
 











GALC – I546 3.3 ± 0.06 9.87 ± 0.2 11.9 3,600 








Table S3. Proportion of side chain buried in the structure, prediction and identified defect  
 
Mutation % Buried ‡ 
Structure-based 
Prediction 
Secreted Localization Defect 
G41S 100 Misfolded No  Misfolded 






T513M 100 Misfolded No ER Misfolded 
I546T § 100 Misfolded No Lysosomal Subtle misfolded 
I583S 100 Misfolded No ER Misfolded 
L618S 100 Misfolded No ER Misfolded 
N279T 99 Misfolded Yes ER 
Hyper-glycosylated 
Not endocytosed 
Y319C 99 Misfolded No ER Misfolded 
P302R 92 Misfolded Yes  Not misfolded 
R515H 82 Uncertain No ER Misfolded 
R63H 79 Uncertain No  Misfolded 
Y551S 78 Uncertain No ER Misfolded 
E215K 57 Not misfolded Yes Lysosomal Not misfolded 




‡ Using the mouse GALC structure (PDB 3ZR5) the proportion of each sidechain that is buried in the structure is 
reported as a percentage of that residue’s entire surface area 















Figure S1. Co-localization of T513M and L618S missense mutations with additional ER markers. 
Representative confocal images of HeLa cells transfected with wild-type and Krabbe disease mutations T513M 
and L618S. Cells were plated onto glass coverslips, fixed and immunostained using monoclonal antibody against 
GALC (green) and the ER markers calnexin (CNX, red) or REEP5 (red). Nuclei were stained with DNA-binding 
dye, DAPI (blue). Scale bar 10 µm. 
  








Figure S2. Co-localization of additional missense mutations of GALC with ER markers. Representative 
confocal images of HeLa cells transfected with wild-type and Krabbe disease mutations I583S, R515H and 
Y319C. Cells were plated onto glass coverslips, fixed and immunostained using monoclonal antibody against 
GALC (green) and the ER markers calreticulin (red) or calnexin (CNX, red). Nuclei were stained with DNA-
binding dye, DAPI (blue). Scale bar 10 µm. 
  









Figure S3. Effect of polymorphic background on trafficking of G270D and Y551S. Representative confocal 
images of HeLa cells transfected with Krabbe mutations G270D and Y551S in polymorphic backgrounds I546 
and T546. Cells were plated onto glass coverslips, fixed and immunostained for GALC (green), the ER marker 














Figure S4. Representative confocal images from untransfected HeLa cells and cells expressing N-
terminally tagged GALC constructs. A) Examples of confocal images containing transfected and untransfected 
cells illustrating undetectable endogenous GALC staining. Cells were plated onto glass coverslips, fixed and 
immunostained using monoclonal antibody against GALC (green) and the ER marker calreticulin (red). B) 
Representative confocal image of untransfected cells with data collected at high laser intensity to illustrate non-
specific staining only. C) Representative confocal image of HeLa cells transfected with an N-terminally tagged 
construct of GALC to illustrate equivalent co-localization with the lysosomal marker cathepsin D (red). 
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